Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05021341 · ClinicalTrials.gov registry record · NA
Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia
A NA study of Glycemia, sponsored by Lindenwood University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT05021341 is a NA study of Glycemia that has completed, run by Lindenwood University. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05021341, a NA study of Glycemia, has completed, sponsored by Lindenwood University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the bioavailability of berberine and dihydroberberine and their impact on changes in plasma concentrations of glucose and insulin.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Berberine
- DIETARY_SUPPLEMENT Dihydroberberine 200
- DIETARY_SUPPLEMENT Dihydroberberine 100
Study Locations (1)
Missouri
- Lindenwood University - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2020-11-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05021341
The ClinicalTrials.gov registry entry for NCT05021341 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindenwood University, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glycemia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05021341 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05021341 about?
NCT05021341 is a clinical study titled "Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia". The purpose of this study is to determine the bioavailability of berberine and dihydroberberine and their impact on changes in plasma concentrations of glucose and insulin.
What is the current status of trial NCT05021341?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2020-06-22. Estimated completion is 2020-11-04.
What conditions does trial NCT05021341 study?
This clinical trial studies the following conditions: Glycemia.
What interventions are being tested in trial NCT05021341?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Berberine (DIETARY_SUPPLEMENT), Dihydroberberine 200 (DIETARY_SUPPLEMENT), Dihydroberberine 100 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05021341?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05021341 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.